|
Post by CM kipper007 on May 15, 2017 19:41:11 GMT
finance.yahoo.com/news/biogen-acquires-remedy-pharmaceuticals-cirara-113000390.htmlBiogen (BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted CIRARA Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted CIRARA Fast Track designation.
|
|
|
Post by CM kipper007 on May 15, 2017 21:27:01 GMT
|
|
|
Post by tmfbmf on May 16, 2017 13:37:06 GMT
They're going after 15% of stroke market, whereas ATHX is going after 85%. $120 million upfront shows how lucrative this can be for ATHX. If they wanted to structure the deal the same, ATHX could get about $250 million up front just for Europe + whatever royalties they are getting. I think GVB prefers, as do I, they take less money upfront and keep a higher percentage of the royalties. No sense in giving up $500 million per year in royalties for and extra $200 million now. I think $50 million upfront is all they need to fund some other projects and get IS to profitability. But that might be cutting it close depending on how they see their expenses ramping up. Maybe they'll take a little more upfront and give up a little more of the royalties just to be comfortable without the threat of more dilution.
|
|
|
Post by CM kipper007 on May 16, 2017 18:51:24 GMT
They're going after 15% of stroke market, whereas ATHX is going after 85%. $120 million upfront shows how lucrative this can be for ATHX. If they wanted to structure the deal the same, ATHX could get about $250 million up front just for Europe + whatever royalties they are getting. I think GVB prefers, as do I, they take less money upfront and keep a higher percentage of the royalties. No sense in giving up $500 million per year in royalties for and extra $200 million now. I think $50 million upfront is all they need to fund some other projects and get IS to profitability. But that might be cutting it close depending on how they see their expenses ramping up. Maybe they'll take a little more upfront and give up a little more of the royalties just to be comfortable without the threat of more dilution. I hope they do go after the 85%. After seeing OCAT sell out my second biggest fear is the company selling out.
|
|